Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.56 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9518171 | 1.00 | SSTR4 (0.56) | SSTR4GRIA4MAPK1KDM1ASMN1; SMN2 | |
| SCHEMBL12269958 | 0.83 | SMN1; SMN2 (0.68) | SSTR4GRIA4MAPK1KDM1ASMN1; SMN2 | |
| SCHEMBL294182 | 0.83 | SMN1; SMN2 (0.68) | SSTR4GRIA4MAPK1KDM1ASMN1; SMN2 | |
| SCHEMBL11486073 | 0.83 | SSTR4 (0.49) | SSTR4GRIA4MAPK1KDM1ASMN1; SMN2 | |
| SCHEMBL11486071 | 0.83 | SSTR4 (0.49) | SSTR4GRIA4MAPK1KDM1ASMN1; SMN2 | |
| SCHEMBL15591888 | 0.83 | SSTR4 (0.67) | SSTR4GRIA4MAPK1KDM1ASMN1; SMN2 | |
| SCHEMBL5531089 | 0.81 | SMN1; SMN2 (0.69) | KDM1ASMN1; SMN2NPSR1MAOB | |
| SCHEMBL20696269 | 0.81 | SMN1; SMN2 (0.69) | KDM1ASMN1; SMN2NPSR1MAOB | |
| SCHEMBL8294081 | 0.81 | SMN1; SMN2 (0.69) | KDM1ASMN1; SMN2NPSR1MAOB | |
| SCHEMBL31018747 | 0.81 | SMN1; SMN2 (0.69) | KDM1ASMN1; SMN2NPSR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-24 | — | — | US | disclosed |
| EP-0559743-A1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE. | PFIZER HOSPITAL PROD (US) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992009566-A1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE | PFIZER INC. (US) | 1992-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK10, MAP3K1 | SSTR4 3983/4885GRIA4 3271/4885MAPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.